<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">phkinetica</journal-id><journal-title-group><journal-title xml:lang="ru">Фармакокинетика и Фармакодинамика</journal-title><trans-title-group xml:lang="en"><trans-title>Pharmacokinetics and Pharmacodynamics</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2587-7836</issn><issn pub-type="epub">2686-8830</issn><publisher><publisher-name>ООО «Издательство ОКИ»</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.37489/2587-7836-2023-3-68-76</article-id><article-id custom-type="elpub" pub-id-type="custom">phkinetica-383</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ДОКЛИНИЧЕСКИЕ ИССЛЕДОВАНИЯ ФАРМАКОДИНАМИКИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>PRECLINICAL PHARMACODYNAMICS STUDIES</subject></subj-group></article-categories><title-group><article-title>Исследование поведенческих эффектов новых фосфорилированных тиосемикарбазидов в эксперименте</article-title><trans-title-group xml:lang="en"><trans-title>Experimental investigation of the behavioral effects of new phosphorylated thiosemicarbazides</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6219-6246</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Никитина</surname><given-names>А. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Nikitina</surname><given-names>A. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Никитина Анастасия Вадимовна - Ассистент кафедры фармакологии</p><p>Казань</p></bio><bio xml:lang="en"><p>Anastasiya V. Nikitina - Assistant of the Department of Pharmacology</p><p>Kazan</p></bio><email xlink:type="simple">namovol@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3515-0845</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Семина</surname><given-names>И. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Semina</surname><given-names>I. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Семина Ирина Ивановна - д. м. н., профессор кафедры фармакологии,заведующая Центральной научно-исследовательской лабораторией</p><p>Казань</p></bio><bio xml:lang="en"><p>Irina I. Semina - Dr. Sci (Med.), Professor of the Department of Pharmacology, Head of the Central Research Laboratory</p><p>Kazan</p></bio><email xlink:type="simple">seminai@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5773-867X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Никитин</surname><given-names>Д. О.</given-names></name><name name-style="western" xml:lang="en"><surname>Nikitin</surname><given-names>D. O.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Никитин Дмитрий Олегович - Ассистент кафедры фармакологии</p><p>Казань</p></bio><bio xml:lang="en"><p>Dmitry O. Nikitin - Assistant of the Department of Pharmacology</p><p>Kazan</p></bio><email xlink:type="simple">richard4777@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8093-7095</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Гаврилова</surname><given-names>Е. Л.</given-names></name><name name-style="western" xml:lang="en"><surname>Gavrilova</surname><given-names>E. L.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Гаврилова Елена Леонидовна - Заведующая кафедрой органической химии имени академика А.Е. Арбузова</p><p>Казань</p></bio><bio xml:lang="en"><p>Elena L. Gavrilova - Head of the Department of Organic Chemistry named after academician A.E. Arbuzov</p><p>Kazan</p></bio><email xlink:type="simple">gavrilova_elena_@mail.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1426-0722</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Крутов</surname><given-names>И. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Krutov</surname><given-names>I. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Крутов Иван Алексеевич - к. х. н., доцент кафедры органической химииимени академика А.Е. Арбузова</p><p>Казань</p></bio><bio xml:lang="en"><p>Ivan A. Krutov - PhD, Cand. Sci. (Chemical) of the Department of Organic Chemistry named after academician A.E. Arbuzov</p><p>Kazan</p></bio><email xlink:type="simple">rburangulova@mail.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3330-9157</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Исаева</surname><given-names>А. О.</given-names></name><name name-style="western" xml:lang="en"><surname>Isaeva</surname><given-names>A. O.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Исаева Анастасия Олеговна - Заведующая комплексной лабораторией «Структура и состав органических веществ»</p><p>Казань</p></bio><bio xml:lang="en"><p>Anastasia O. Isaeva - Head of the complex laboratory “Structure and composition of organic substances”</p><p>Kazan</p></bio><email xlink:type="simple">tasaisaeva@gmail.com</email><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБОУ ВО «Казанский государственный медицинский университет» Министерства здравоохранения Российской Федерации</institution><country>Россия</country></aff><aff xml:lang="en"><institution>SBEI НЕ Kazan SМU МОН Russia</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ФГБОУ ВО «Казанский национальный исследовательский технологический университет»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Kazan National Research Technological University</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2023</year></pub-date><pub-date pub-type="epub"><day>03</day><month>11</month><year>2023</year></pub-date><volume>0</volume><issue>3</issue><fpage>68</fpage><lpage>76</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Никитина А.В., Семина И.И., Никитин Д.О., Гаврилова Е.Л., Крутов И.А., Исаева А.О., 2023</copyright-statement><copyright-year>2023</copyright-year><copyright-holder xml:lang="ru">Никитина А.В., Семина И.И., Никитин Д.О., Гаврилова Е.Л., Крутов И.А., Исаева А.О.</copyright-holder><copyright-holder xml:lang="en">Nikitina A.V., Semina I.I., Nikitin D.O., Gavrilova E.L., Krutov I.A., Isaeva A.O.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.pharmacokinetica.ru/jour/article/view/383">https://www.pharmacokinetica.ru/jour/article/view/383</self-uri><abstract><sec><title>Актуальность</title><p>Актуальность. Известно, что существующая лекарственная терапия когнитивных расстройств характеризуется невысокими показателями эффективности и безопасности, а также симптоматической направленностью. Поэтому изыскание новых лекарственных средств в данной сфере является актуальным вопросом, решением которого могут стать фосфорилированные производные тиосемикарбазидов (ФТК), обладающие мультитаргетным механизмом действия.</p></sec><sec><title>Цель</title><p>Цель. Изучение острой токсичности и влияния на поведение мышей ФТК.</p></sec><sec><title>Методы</title><p>Методы. Объекты исследования — 2 новых соединения ряда ФТК: 2-[2-(Дифенилфосфорил)ацетил]гидразинкарботиоамид (Т7) и 2-[2-(Дифенилфосфорил)ацетил]-N-фенилгидразинкарботиоамид (Т8). Препарат сравнения — гидразид дифенилфосфорилуксусной кислоты (фосеназид). После определения острой токсичности при внутрибрюшинном однократном введении, влияние ФТК на поведение мышей изучено на моделях «Открытое поле» (ОП), «Приподнятый крестообразный лабиринт» (ПКЛ), «Тёмно-светлая камера» (ТСК) и «Поведенческое отчаяние» (ПО). Для статистического анализа применяли программу GraphPadPrism 8.0.1 с вычислением t-критерия Стьюдента.</p></sec><sec><title>Результаты</title><p>Результаты. Установлено, что новые ФТК обладают меньшей токсичностью по сравнению с фосеназидом. Поведенческое тестирование показало, что в/б введение Т8 способствовало увеличению исследовательской (6 и 12 мг/кг) и двигательной (12 мг/кг) активности на модели ОП, развитию анксиолитического эффекта в тестах ПКЛ (12 мг/кг) и ТСК (6 мг/кг), а в тесте ПО (12 мг/кг) — антидепрессивного действия. При в/б введении Т7 отмечалось увеличение двигательной активности в тесте ОП (16 мг/кг).</p></sec><sec><title>Вывод</title><p>Вывод. Соединения ряда ФТК являются перспективными для дальнейшего синтеза и разработки в качестве потенциальных лекарственных препаратов с различным спектром психотропной активности.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Relevance</title><p>Relevance. It is known that the existing drug therapy for cognitive disorders is characterized by low rates of eﬃcacy and safety, as well as symptomatic orientation. Therefore, the search for new drugs in this area is an urgent issue, the solution of which can be phosphorylated derivatives of thiosemicarbazides (PTC), which have a multitarget mechanism of action.</p></sec><sec><title>Aim</title><p>Aim. Study of acute toxicity and behavioral eﬀects of PTC in mice.</p></sec><sec><title>Methods</title><p>Methods. The objects of study are 2 new compounds of the PTC series: 2-[2-(Diphenylphosphoryl)acetyl]hydrazinecarbothioamide (T7) and 2-[2-(Diphenylphosphoryl) acetyl]-N-phenylhydrazinecarbothioamide (T8). The reference drug is diphenylphosphorylacetic acid hydrazide (phosenazid). After determining the acute toxicity with a single intraperitoneal injection, the eﬀect of PTK on the behavior of mice was studied in the models "Open ﬁeld" (OP), "Elevated plus maze" (EPM), "Dark-light chamber" (DLC) and "Behavioral despair" (BD). For statistical analysis, the GraphPadPrism 8.0.1 program was used with the calculation of Student's t-test.</p></sec><sec><title>Results</title><p>Results. It has been established that new PTC are less toxic than fosenazid. Behavioral testing showed that i.m. administration of T8 in test "OP" contributed to an increase in exploratory (6 and 12 mg/kg) and motor (12 mg/kg) activity, the development of an anxiolytic eﬀect in the tests "EPM" (12 mg/kg) and "DLC" (6 mg / kg), and in "BD" (12 mg / kg) antidepressant eﬀect. With the intravenous administration of T7, an increase in motor activity in the “OP” (16 mg / kg) was noted.</p></sec><sec><title>Conclusion</title><p>Conclusion. Compounds of a number of PTC are promising for further synthesis and development as potential drugs with a diﬀerent spectrum of psychotropic activitys.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>фосфорилированные тиосемикарбазиды</kwd><kwd>открытое поле</kwd><kwd>приподнятый крестообразный лабиринт</kwd><kwd>тёмно-светлая камера</kwd><kwd>психотропные свойства</kwd></kwd-group><kwd-group xml:lang="en"><kwd>phosphorylated thiosemicarbazides</kwd><kwd>open field</kwd><kwd>elevated plus maze</kwd><kwd>dark-light chamber</kwd><kwd>psychotropic properties</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Gopalakrishnan M, Sureshkumar P, Thanusu J, Kanagarajan V. Unusual formation of N-hydroxy-3,3-dimethyl-2,6-diarylpiperidin-4-one and its thiosemicarbazide derivative–synthesis and antimicrobial activity. Pharmaceutical Chemistry Journal. 2008;42(5):271–276. DOI: 10.1007/s11094-008-0104-z.</mixed-citation><mixed-citation xml:lang="en">Gopalakrishnan M, Sureshkumar P, Thanusu J, Kanagarajan V. Unusual formation of N-hydroxy-3,3-dimethyl-2,6-diarylpiperidin-4-one and its thiosemicarbazide derivative–synthesis and antimicrobial activity. Pharmaceutical Chemistry Journal. 2008;42(5):271–276. DOI: 10.1007/s11094-008-0104-z.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Banerjee D, Yogeeswari P, Bhat P, et al. Novel isatinyl thiosemicarbazones derivatives as potential molecule to combat HIV-TB co-infection. Eur J Med Chem. 2011 Jan;46(1):106–121. DOI: 10.1016/j.ejmech.2010.10.020.</mixed-citation><mixed-citation xml:lang="en">Banerjee  D,  Yogeeswari  P,  Bhat  P,  et  al.  Novel  isatinyl thiosemicarbazones derivatives as potential molecule to combat HIV-TB co-infection. Eur J Med Chem. 2011 Jan;46(1):106–121. DOI: 10.1016/j.ejmech.2010.10.020.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Siddiqui N, Singh O. Antibacterial activity of some 4-N-substituted thiosemicarbazidesand thiosemicarbazones. Indian Journal of Pharmaceutical Sciences. 2003;65 (4):423–425.</mixed-citation><mixed-citation xml:lang="en">Siddiqui N, Singh O. Antibacterial activity of some 4-N-substituted thiosemicarbazidesand thiosemicarbazones. Indian Journal of Pharmaceutical Sciences. 2003;65 (4):423–425.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Majumdar P, Pati A, Patra M, et al. Acid hydrazides, potent reagents for synthesis of oxygen-, nitrogen-, and/or sulfur-containing heterocyclic rings. Chem Rev. 2014 Mar 12;114(5):2942–2977. DOI: 10.1021/cr300122t.</mixed-citation><mixed-citation xml:lang="en">Majumdar P, Pati A, Patra M, et al. Acid hydrazides, potent reagents for synthesis of oxygen-, nitrogen-, and/or sulfur-containing heterocyclic rings. Chem Rev. 2014 Mar 12;114(5):2942–2977. DOI: 10.1021/cr300122t.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Siwek A, Stefańska J, Dzitko K, Ruszczak A. Antifungal effect of 4-arylthiosemicarbazides against Candida species. Search for molecular basis of antifungal activity of thiosemicarbazide derivatives. J Mol Model. 2012 Sep;18(9):4159–4170. DOI: 10.1007/s00894-012-1420-5.</mixed-citation><mixed-citation xml:lang="en">Siwek A, Stefańska J, Dzitko K, Ruszczak A. Antifungal effect of 4-arylthiosemicarbazides against Candida species. Search for molecular basis of antifungal activity of thiosemicarbazide derivatives. J Mol Model. 2012 Sep;18(9):4159–4170. DOI: 10.1007/s00894-012-1420-5.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Thomas AM, Naik AD, Nethaji M, Chakravarty AR. Synthesis, crystal structure andphoto-induced DNA cleavage activity of ternary copper(II) – thiosemicarbazonecomplexes having heterocyclic bases. Inorganica Chimica Acta. 2004;357:2315–2323. DOI: 10.1016/j.ica.2004.01.031.</mixed-citation><mixed-citation xml:lang="en">Thomas AM, Naik AD, Nethaji M, Chakravarty AR. Synthesis, crystal structure andphoto-induced DNA cleavage activity of ternary copper(II) – thiosemicarbazonecomplexes having heterocyclic bases. Inorganica  Chimica  Acta.  2004;357:2315–2323.  DOI:  10.1016/j.ica.2004.01.031.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Seleem HS, El-Shetary BA, Khalil SME, et al. Structural diversity in copper(II) complexes of bis(thiosemicarbazone) and bis(semicarbazone) ligands. Journal of Coordination Chemistry. 2005;58:479–493. DOI: 10.1080/00958970512331334269.</mixed-citation><mixed-citation xml:lang="en">Seleem HS, El-Shetary BA, Khalil SME, et al. Structural diversity in copper(II) complexes of bis(thiosemicarbazone) and bis(semicarbazone) ligands. Journal of Coordination Chemistry. 2005;58:479–493. DOI: 10.1080/00958970512331334269.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Reis CM, Pereira DS, Paiva Rde O, et al. Microwave-assisted synthesis of new N1,N4-substituted thiosemicarbazones. Molecules. 2011 Dec 20;16(12):10668–10684. DOI: 10.3390/molecules161210668.</mixed-citation><mixed-citation xml:lang="en">Reis CM, Pereira DS, Paiva Rde O, et al. Microwave-assisted synthesis of new N1,N4-substituted thiosemicarbazones. Molecules. 2011 Dec 20;16(12):10668–10684. DOI: 10.3390/molecules161210668.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Plech T, Wujec M, Siwek A, Kosikowska U, Malm A. Synthesis and antimicrobial activity of thiosemicarbazides, s-triazoles and their Mannich bases bearing 3-chlorophenyl moiety. Eur J Med Chem. 2011 Jan;46(1): 241–248. DOI: 10.1016/j.ejmech.2010.11.010.</mixed-citation><mixed-citation xml:lang="en">Plech T, Wujec M, Siwek A, Kosikowska U, Malm A. Synthesis and antimicrobial activity of thiosemicarbazides, s-triazoles and their Mannich bases bearing 3-chlorophenyl moiety. Eur J Med Chem. 2011 Jan;46(1): 241–248. DOI: 10.1016/j.ejmech.2010.11.010.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Газиева Г.А., Кравченко А.Н. Тиосемикарбазиды в синтезе пяти-и шестичленных гетероциклических соединений. Успехи химии. 2012;81(6):494-523. DOI: 10.1070/RC2012v081n06ABEH004235.</mixed-citation><mixed-citation xml:lang="en">Gazieva GA, Kravchenko AN. Thiosemicarbazides in the synthesis of five- and six-membered heterocyclic compounds. Russ Chem  Rev.  2012;81(6):494–523.  (In  Russ.)  DOI:  10.1070/RC2012v081n06ABEH004235.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Hisle-Gorman E, Susi A, Stokes T, et al. Prenatal, perinatal, and neonatal risk factors of autism spectrum disorder. Pediatric research. 2018;84(2):190–198. DOI: 10.1038/pr.2018.23.</mixed-citation><mixed-citation xml:lang="en">Hisle-Gorman E, Susi A, Stokes T, et al. Prenatal, perinatal, and neonatal risk factors of autism spectrum disorder. Pediatric research. 2018;84(2):190–198. DOI: 10.1038/pr.2018.23.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Varvaresou A, Siatra-Papastaikoudi T, Dalla Tsotinis A, et al. Synthesis, lipophilicity and biological evaluation of indole-containing derivatives of 1,3,4-thiadiazole and 1,2, 4-triazole. Farmaco. 1998 May 30;53(5):320–326. DOI: 10.1016/s0014-827x(98)00024-x.</mixed-citation><mixed-citation xml:lang="en">Varvaresou A, Siatra-Papastaikoudi T, Dalla Tsotinis A, et al. Synthesis, lipophilicity and biological evaluation of indole-containing derivatives of 1,3,4-thiadiazole and 1,2, 4-triazole. Farmaco. 1998 May 30;53(5):320–326. DOI: 10.1016/s0014-827x(98)00024-x.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Никитин Д.О., Плотникова А.В., Галимова Л.Ф. и др. Исследование психотропных свойств новых аналогов транквилизатора фосеназида. Современные проблемы науки и образования. 2016;(6):138– 138. URL: https://science-education.ru/ru/article/view?id=25696</mixed-citation><mixed-citation xml:lang="en">Nikitin DO, Plotnikova AV, Galimova LF, et al, A study of psychotropic properties of the new analogues of tranquilizer phosenazid. Modern problems of science and education. 2016;(6):138–138. (In Russ.) URL: https://science-education.ru/ru/article/view?id=25696</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Семина И.И., Байчурина А.З. Разработка новых потенциальных лекарственных средств с психотропной активностью среди фосфорилацетогидразидов и других производных фосфорилированных карбоновых кислот — приоритетное направление казанской школы психофармакологов. Казанский медицинский журнал. 2016;97(1):148–155. DOI: 10.17750/KMJ2016-148.</mixed-citation><mixed-citation xml:lang="en">Semina II, Baychurina AZ. Development of new potential drugs with psychotropic activity among phosphorylacetohydrazides and other phosphorylated carboxylic acids derivatives — priority area of Kazan school of psychopharmacologists. Kazan Medical Journal. 2016;97(1):148–155. (In Russ.) DOI: 10.17750/KMJ2016-148.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Семина И.И., Шиловская Е.В., Тарасова Р.И. и др. Механизмы психотропного действия гидразидов фосфорилированных карбоновых кислот. Химико-фармацевтический журнал. 2002;36(4):3–6. DOI: 10.30906/0023-1134-2002-36-4-3-6.</mixed-citation><mixed-citation xml:lang="en">Semina II, Shilovskaya EV, Tarasova RI, et al. Mekhanizmy psihotropnogo dejstviya gidrazidov fosforilirovannyh karbonovyh kislot. Pharmaceutical Chemistry Journal. 2002;36(4):3–6. (In Russ.) DOI: 10.30906/0023-1134-2002-36-4-3-6.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Миронов А.Н., Бунятян Н.Д., Васильев А.Н. и др. Руководство по проведению доклинических исследований лекарственных средств. Часть 1 / под ред. А.Н. Миронова. М.: Гриф и К; 2012.</mixed-citation><mixed-citation xml:lang="en">Mironov AN, Bunyatyan ND, Vasiliev AN, et al. Guidelines for conducting preclinical studies of drugs. Part 1 / Ed by AN Mironova. Moscow: Grif i K; 2012. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Seibenhener ML, Wooten MC. Use of the Open Field Maze to measure locomotor and anxiety-like behavior in mice. J Vis Exp. 2015 Feb 6;(96):e52434. DOI: 10.3791/52434.</mixed-citation><mixed-citation xml:lang="en">Seibenhener ML, Wooten MC. Use of the Open Field Maze to measure locomotor and anxiety-like behavior in mice. J Vis Exp. 2015 Feb 6;(96):e52434. DOI: 10.3791/52434.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Martin-Arenas FJ, Pintado CO. Results of the Open Field Test at different light intensities in C57 mice. Proceedings of Measuring Behavior. 2014:1-5. DOI: 10.13140/RG.2.2.29920.74247.</mixed-citation><mixed-citation xml:lang="en">Martin-Arenas FJ, Pintado CO. Results of the Open Field Test at different light intensities in C57 mice. Proceedings of Measuring Behavior. 2014:1-5. DOI: 10.13140/RG.2.2.29920.74247.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Walf AA, Frye CA. The use of the elevated plus maze as an assay of anxiety-related behavior in rodents. Nat Protoc. 2007;2(2):322–328. DOI: 10.1038/nprot.2007.44.</mixed-citation><mixed-citation xml:lang="en">Walf AA, Frye CA. The use of the elevated plus maze as an assay of anxiety-related behavior in rodents. Nat Protoc. 2007;2(2):322–328. DOI: 10.1038/nprot.2007.44.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Гарибова Т. Л., Крайнева В. А., Воронина Т. А. Поведенческие экспериментальные модели депрессии. Фармакокинетика и фармакодинамика. 2017;(3):14–19.</mixed-citation><mixed-citation xml:lang="en">Garibova TL, Kraineva VA, Voronina TA. Animal models of depression. Farmakokinetika i farmakodinamika = Pharmacokinetics and pharmacodynamics. 2017;(3):14–19. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Sabatos-DeVito M, Murias M, Dawson G, et al. Methodological considerations in the use of Noldus EthoVision XT video tracking of children with autism in multi-site studies. Biol Psychol. 2019 Sep;146:107712. DOI: 10.1016/j.biopsycho.2019.05.012.</mixed-citation><mixed-citation xml:lang="en">Sabatos-DeVito M, Murias M, Dawson G, et al. Methodological considerations in the use of Noldus EthoVision XT video tracking of children with autism in multi-site studies. Biol Psychol. 2019 Sep;146:107712. DOI: 10.1016/j.biopsycho.2019.05.012.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Березовская И. В. Классификация химических веществ по параметрам острой токсичности при парентеральных способах введения. Химико-фармацевтический журнал. 2003;37(3):32–34. DOI: 10.30906/0023-1134-2003-37-3-32-34.</mixed-citation><mixed-citation xml:lang="en">Berezovskaya IV. Classification of chemicals according to the parameters of acute toxicity in parenteral administration. Pharmaceutical Chemistry Journal. 2003;37(3):32–34. (In Russ.) DOI: 10.30906/0023-1134-2003-37-3-32-34.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Васенина Е.Е., Левин О.С., Сонин А.Г. Современные тенденции в эпидемиологии деменции и ведении пациентов с когнитивными нарушениями. Журнал неврологии и психиатрии им. С.С. Корсакова. Спецвыпуски. 2017;117(6 2):87-95. DOI: 10.17116/jnevro20171176287-95.</mixed-citation><mixed-citation xml:lang="en">Vasenina EE, Levin OS, Sonin AG. Modern trends in epidemiology of dementia and management of patients with cognitive impairment. Zh Nevrol Psikhiatr Im S S Korsakova. 2017;117(6 2):87–95. (In Russ.) DOI: 10.17116/jnevro20171176287-95.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Науменко А.А., Громова Д.О., Трофимова Н.В., Преображенская И.А. Диагностика и лечение болезни Альцгеймера. Неврология, нейропсихиатрия, психосоматика. 2016;8(4):91–97. doi: 10.14412/2074-2711-2016-4-91-97.</mixed-citation><mixed-citation xml:lang="en">Naumenko AA, Gromova DO, Trofimova NV, Preobrazhenskaya IS. Alzheimer’s disease: diagnosis and treatment. Neurology, Neuropsychiatry, Psychosomatics. 2016;8(4):91-97. (In Russ.) doi: 10.14412/2074-2711-2016-4-91-97.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
